Literature DB >> 20368835

Proteome analysis of differential protein expression in cervical cancer cells after paclitaxel treatment.

Eun-Kyoung Yim1, Jun-Sang Bae, Seung-Bak Lee, Keun-Ho Lee, Chan-Joo Kim, Sung-Eun Namkoong, Soo-Jong Um, Jong-Sup Park.   

Abstract

PURPOSE: It is well known that infection with HPV (human papillomavirus) is the main cause of cervical cancer and certain types of HPV are recognized as carcinogens. At present, there is little information regarding the antineoplastic mechanism of paclitaxel against cervical carcinoma cells. We thus tried to analyze differential protein expression and antineoplastic mechanism-related proteins after paclitaxel treatment on cervical cancer cells by using a proteomic analysis and to investigate the mechanism of action.
MATERIALS AND METHODS: Using proteomics analysis including 2-DE and MALDI-TOF-MS, we detected the antineoplastic mechanism-related proteins. Then, we performed western blot analysis for apoptosis- and transformation-related proteins to confirm expression patterns derived from proteome analysis after paclitaxel treatment.
RESULTS: We identified several cellular proteins that are responsive to paclitaxel treatment in HeLa cells using proteomics methods. Paclitaxel treatment elevated mainly apoptosis, immune response and cell cycle check point-related proteins. On the other hand, paclitaxel treatment diminished growth factor/oncogene-related proteins and transcription regulation-related proteins. Also, in the HPV-associated cervical carcinoma cells, paclitaxel demonstrated anti-proliferative activity through the membrane death receptor-mediated apoptotic pathway and the mitochondrial-mediated pathway.
CONCLUSION: Identification and characterization of functionally modulated proteins involved in anti-cancer regulatory events should lead to a better understanding of the long-term actions of paclitaxel at the molecular level and will contribute to the future development of novel therapeutic drug treatments based upon current therapies.

Entities:  

Keywords:  Apoptosis; Cervical carcinoma; HPV; Paclitaxel; Proteomics

Year:  2004        PMID: 20368835      PMCID: PMC2843878          DOI: 10.4143/crt.2004.36.6.395

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  23 in total

1.  Docetaxel versus paclitaxel for antiangiogenesis.

Authors:  Angelo Vacca; Domenico Ribatti; Monica Iurlaro; Francesca Merchionne; Beatrice Nico; Roberto Ria; Franco Dammacco
Journal:  J Hematother Stem Cell Res       Date:  2002-02

2.  Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.

Authors:  Kylie A Hotchkiss; Anthony W Ashton; Radma Mahmood; Robert G Russell; Joseph A Sparano; Edward L Schwartz
Journal:  Mol Cancer Ther       Date:  2002-11       Impact factor: 6.261

Review 3.  Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.

Authors:  H A Burris
Journal:  Semin Oncol       Date:  2001-02       Impact factor: 4.929

4.  Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.

Authors:  Lee M Krug; Vincent A Miller; Daniel A Filippa; Ennapadam Venkatraman; Kenneth K Ng; Mark G Kris
Journal:  Lung Cancer       Date:  2003-02       Impact factor: 5.705

Review 5.  Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.

Authors:  C Belani; T Lynch
Journal:  Semin Oncol       Date:  2001-02       Impact factor: 4.929

6.  A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions.

Authors:  Shahid Mian; Graham Ball; Jo Hornbuckle; Finn Holding; James Carmichael; Ian Ellis; Selman Ali; Geng Li; Stephanie McArdle; Colin Creaser; Robert Rees
Journal:  Proteomics       Date:  2003-09       Impact factor: 3.984

7.  Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.

Authors:  Eunyoung Chun; Ki-Young Lee
Journal:  Biochem Biophys Res Commun       Date:  2004-03-12       Impact factor: 3.575

8.  Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells.

Authors:  Christophe Héliez; Laurent Baricault; Nadia Barboule; Annie Valette
Journal:  Oncogene       Date:  2003-05-22       Impact factor: 9.867

9.  Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.

Authors:  Cristiano Ferlini; Giuseppina Raspaglio; Simona Mozzetti; Mariagrazia Distefano; Flavia Filippetti; Enrica Martinelli; Gabriella Ferrandina; Daniela Gallo; Franco Oreste Ranelletti; Giovanni Scambia
Journal:  Mol Pharmacol       Date:  2003-07       Impact factor: 4.436

Review 10.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

View more
  3 in total

Review 1.  Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture.

Authors:  Debasish Paul; Avinash Kumar; Akshada Gajbhiye; Manas K Santra; Rapole Srikanth
Journal:  Biomed Res Int       Date:  2013-03-17       Impact factor: 3.411

Review 2.  Proteomic Analysis of Anticancer TCMs Targeted at Mitochondria.

Authors:  Yang Wang; Ru-Yuan Yu; Qing-Yu He
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-19       Impact factor: 2.629

3.  PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.

Authors:  Haiyan Zhu; Jun Wu; Wenwen Zhang; Hui Luo; Zhaojun Shen; Huihui Cheng; Xueqiong Zhu
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.